期刊文献+
共找到166篇文章
< 1 2 9 >
每页显示 20 50 100
A pilot study on combination of cryosurgery and ^(125)iodine seed implantation for treatment of locally advanced pancreatic cancer 被引量:38
1
作者 Ke-Cheng Xu Li-Zhi Niu +4 位作者 Yi-Ze Hu Wei-Bing He Yi-Song He Ying-Fei Li Jian-Sheng Zuo 《World Journal of Gastroenterology》 SCIE CAS CSCD 2008年第10期1603-1611,共9页
AIM: To study the therapeutic value of combination o cryosurgery and 125iodine seed implantation for locally advanced pancreatic cancer. METHODS: Forty-nine patients with locally advanced pancreatic cancer (males 36, ... AIM: To study the therapeutic value of combination o cryosurgery and 125iodine seed implantation for locally advanced pancreatic cancer. METHODS: Forty-nine patients with locally advanced pancreatic cancer (males 36, females 13), with a median age of 59 years, were enrolled in the study. Twelve patients had liver metastases. In all cases the tumors were considered unresectable after a comprehensive evaluation. Patients were treated with cryosurgery, which was performed intraoperatively or percutaneously unde guidance of ultrasound and/or computed tomography (CT), and 125iodine seed implantation, which was performed during cryosurgery or post-cryosurgery under guidance of ultrasound and/or CT. A few patients received regional celiac artery chemotherapy. RESULTS: Thirteen patients received intraoperative cryosurgery and 36 received percutaneous cryosurgery Some patients underwent repeat cryosurgery. 125Iodine seed implantation was performed during freezing procedure in 35 patients and 3-9 d after cryosurgery in 14 cases. Twenty patients, 10 of whom had hepaticmetastases received regional chemotherapy. At 3 mo after therapy, CT was repeated to estimate tumor response to therapy. Most patients showed varying degrees of tumor necrosis. Complete response (CR) of tumor was seen in 20.4% patients, partial response (PR), in 38.8%, stable disease (SD), in 30.6%, and progressive disease (PD), in 10.2%. Adverse effects associated with cryosurgery included upper abdomen pain and increased serum amylase. Acute pancreatitis was seen in 6 patients one of whom developed severe pancreatitis. All adverse effects were controlled by medical management with no poor outcome. There was no therapy-related mortality. During a median follow-up of 18 mo (range of 5-40), the median survival was 16.2 mo, with 26 patients (53.1%) surviving for 12 mo or more. Overall, the 6-, 12-, 24- and 36-mo survival rates were 94.9%, 63.1%, 22.8% and 9.5%, respectively. Eight patients had survival of 24 mo or more. The patient with the longest survival (40 mo) is still living without evidence of tumor recurrence. CONCLUSION: Cryosurgery, which is far less invasive than conventional pancreatic resection, and is associated with a low rate of adverse effects, should be the treatment of choice for patients with locally advanced pancreatic cancer. 125Iodine seed implantation can destroy the residual surviving cancer cells after cryosurgery. Hence, a combination of both modalities has a complementary effect. 展开更多
关键词 Pancreatic cancer CRYOSURGERY CRYOABLATION ^^125iodine seed implantation
下载PDF
CT guided ^125iodine seed implantation for portal vein tumor thrombus in primary hepatocellular carcinoma 被引量:46
2
作者 ZHANG Fu-jun LI Chuan-xing +4 位作者 JIAO De-chao ZHANG Nian-hua WU Pei-hong DUAN Guang-feng WU Yue-xia 《Chinese Medical Journal》 SCIE CAS CSCD 2008年第23期2410-2414,共5页
Background This study evaluated the clinical application of CT guided ^125iodine implantation in patients with portal vein tumor thrombus in primary hepatocellular carcinoma. Methods The ten patients (9 males and 1 f... Background This study evaluated the clinical application of CT guided ^125iodine implantation in patients with portal vein tumor thrombus in primary hepatocellular carcinoma. Methods The ten patients (9 males and 1 female, aged from 36 to 72 years) with portal vein tumor thrombus accompanying hepatocellular carcinoma had been treated with comprehensive therapy including surgery, transcatheter arterial chemoembolization, radiotherapy ablation, microwave ablation or percutaneous ethanol injection. The average diameter of each tumor thrombus was 21.5 mm × 30.5 mm. Seeds of 30 MBq ^125I were implanted 5 mm apart within the portal vein tumor thrombus. The follow-up after 4 months included enhanced spiral CT. Results CT screening of the tumours indicated that 4 out of 10 patients showed complete response to the therapy, 5 partial response and 1 stable disease. Adverse effects included aggravated abdominal dropsy and temporarily increased transaminase, which were controlled by medical management. Severe complications such as haemorrhage, biliary fistula hepatic abscess, pancreatic fistula and hepatic function failure were not observed. Implanted seeds migrated to lung and left hepatic lobe in 1 case. Conclusion CT guided implantation of ^125iodine seeds, can effectively treat portal vein tumor thrombus accompanying hepatocellular carcinoma with minimal damage and few complications. 展开更多
关键词 ^^125I iodine seed implantation portal vein tumor thrombus BRACHYTHERAPY primary hepatocellular carcinoma
原文传递
Intraoperative radiofrequency ablation combined with ^(125)iodine seed implantation for unresectable pancreatic cancer 被引量:22
3
作者 Yi-Ping Zou Wei-Min Li +4 位作者 Fang Zheng Fu-Cheng Li Hui Huang Ji-Dong Du Hao-Run Liu 《World Journal of Gastroenterology》 SCIE CAS CSCD 2010年第40期5104-5110,共7页
AIM: To evaluate the feasibility, efficacy and safety of intraoperative radiofrequency ablation (RFA) combined with 125 iodine seed implantation for unresectable pancreatic cancer. METHODS: Thirty-two patients (21 mal... AIM: To evaluate the feasibility, efficacy and safety of intraoperative radiofrequency ablation (RFA) combined with 125 iodine seed implantation for unresectable pancreatic cancer. METHODS: Thirty-two patients (21 males and 11 females) at the age of 68 years (range 48-90 years) with unresectable locally advanced pancreatic cancer admitted to our hospital from January 2006 to May 2008 were enrolled in this study. The tumor, 4-12 cm in diameter, located in pancreatic head of 23 patients and in pancreatic body and tail of 9 patients, was found to be unresectable during operation. Diagnosis of pancreatic cancer was made through intraoperative biopsy. Patients were treated with FRA combined with 125 iodine seed implantation. In brief, a RFA needle was placed, which was confirmed by intraoperative ultrasound to decrease the potential injury of surrounding vital structures, a 125 iodine seed was implanted near the blood vessels and around the tumor border followed by bypass palliative procedure (cholangio-jejunostomy and/or gastrojejunostomy) in 29 patients.RESULTS: The serum CA 19-9 level was decreased from 512 ± 86 U/mL before operation to 176 ± 64 U/mL, 108 ± 42 U/mL and 114 ± 48 U/mL, respectively, 1, 3 and 6 mo after operation (P < 0.05). The pain score on day 7 after operation, 1 and 3 mo after combined therapy was decreased from 5.86 ± 1.92 before operation to 2.65 ± 1.04, 1.65 ± 0.88 and 2.03 ± 1.16, respectively, after operation (P < 0.05). The rate of complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) in 32 patients was 21.8% (7/32), 56.3% (18/32), 15.6% (5/32) and 6.3% (2/32), respectively, 6 mo after operation, with a median overall survival time of 17. 5 mo. The median survival time of patients at stage Ⅲ was longer than that of those at stage Ⅳ (19 mo vs 10 mo, P = 0.0026). The median survival time of patients who received and did not receive chemotherapy after operation was 20 mo and 16 mo, respectively (P = 0.0176). Of the 32 patients, 3 (10.6%) experienced postoperative complications including transient biliary leaks in 2 patients and acute pancreatitis in 1 patient. All the patients recovered well after conservative support treatment. CONCLUSION: Intraoperative RFA combined with 125 iodine seed implantation is a feasible and safe procedure for unresectable pancreatic cancer with acceptable minor complications, and can prolong the survival time of patients, especially those at stage Ⅲ. 展开更多
关键词 Unresectable pancreatic cancer Radiofrequency ablation 125 iodine seed implantation
下载PDF
A case report of iodine-125 seed placement during operation for the treatment of advanced gallbladder carcinoma with septic shock 被引量:1
4
作者 Zhuo Zhong Fei Gao +2 位作者 Zhuo Lv Zhihui Zhong De Long 《Oncology and Translational Medicine》 CAS 2021年第2期95-98,共4页
This case report describes a patient with advanced gallbladder cancer who developed septic shock associated with iodine-125(^(125)I)seed implantation.The treatment process is described to provide a clinical reference ... This case report describes a patient with advanced gallbladder cancer who developed septic shock associated with iodine-125(^(125)I)seed implantation.The treatment process is described to provide a clinical reference for similar cases.A 52-year-old woman with recurrence of advanced gallbladder cancer underwent ^(125)I seed implantation and developed postoperative sepsis with septic shock.The blood culture suggested infection with Aeromonas caviae and Enterococcus faecalis.Vancomycin and imipenem were immediately administered according to the drug sensitivity results,along with immunoglobulin therapy and vasoactive drugs.The patient’s condition gradually stabilized after comprehensive treatment.Sepsis with septic shock is a rare but potentially fatal complication of ^(125)I seed implantation.Timely administration of broad-spectrum antibiotics,immunoglobulin therapy,and vasoactive drugs is very important to stabilize the patient’s condition.Our treatment of this patient can serve as a reference for clinicians to manage this complication in similar cases. 展开更多
关键词 advanced gallbladder cancer ^^(125)I seed placement SEPSIS septic shock
下载PDF
Implanting iodine-125 seeds into rat dorsal root ganglion for neuropathic pain: neuronal microdamage without impacting hind limb motion
5
作者 Ling Jiao Tengda Zhang +5 位作者 Huixing Wang Wenyi Zhang Saijun Fan Xiaodong Huo Baosen Zheng Wenting Ma 《Neural Regeneration Research》 SCIE CAS CSCD 2014年第12期1204-1209,共6页
The use of iodine-125 (L251) in cancer treatment has been shown to relieve patients' pain. Consid- ering dorsal root ganglia are critical for neural transmission between the peripheral and central nervous systems, ... The use of iodine-125 (L251) in cancer treatment has been shown to relieve patients' pain. Consid- ering dorsal root ganglia are critical for neural transmission between the peripheral and central nervous systems, we assumed that 125I could be implanted into rat dorsal root ganglia to provide relief for neuropathic pain. 125I seeds with different radioactivity (0, 14.8, 29.6 MBq) were im- planted separately through L4-5 and L5-6 intervertebral foramen into the vicinity of the L5 dorsal root ganglion, von Frey hair results demonstrated the mechanical pain threshold was elevated after implanting 125I seeds from the high radioactivity group. Transmission electron microscopy revealed that nuclear membrane shrinkage, nucleolar margination, widespread mitochondrial swelling, partial vacuolization, lysosome increase, and partial endoplasmic reticulum dilation were visible at 1,440 hours in the low radioactivity group and at 336 hours in the high radio- activity group. Abundant nuclear membrane shrinkage, partial fuzzy nuclear membrane and endoplasmic reticulum necrosis were observed at 1,440 hours in the high radioactivity group. No significant difference in combined behavioral scores was detected between preoperation and postoperation in the low and high radioactivity groups. These results suggested that the mechan- ical pain threshold was elevated after implanting 125I seeds without influencing motor functions of the hind limb, although cell injury was present. 展开更多
关键词 nerve regeneration iodine-125 ANALGESIA radioactive seeds ULTRASTRUCTURE pain threshold dorsal root ganglion injury neuropathic pain neural regeneration
下载PDF
Similar therapeutic effects of ^(125I) seed radiotherapy andγ-ray radiotherapy on lacrimal gland adenoid cystic carcinoma 被引量:5
6
作者 Rui Liu Ji-Tong Shi +4 位作者 Xin Ge Ben-Tao Yang Hong Zhang Jing-Xue Zhang Jian-Min Ma 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2021年第4期547-553,共7页
AIM:To evaluate the survival outcomes of patients with lacrimal gland adenoid cystic carcinoma who underwent eye-sparing surgery combined with ^(125I)seed implantation radiotherapy or local externalγ-ray radiotherapy... AIM:To evaluate the survival outcomes of patients with lacrimal gland adenoid cystic carcinoma who underwent eye-sparing surgery combined with ^(125I)seed implantation radiotherapy or local externalγ-ray radiotherapy.METHODS:In this retrospective comparative case series,the clinical records of 27 primary and 8 recurrent patients were reviewed.Univariate and multivariate analyses were used to identify risk factors associated with distant metastasis(DM),and the overall survival(OS)after the initial surgery was analyzed.RESULTS:The median follow-up after radiotherapy was 36 mo(range 6-120 mo).At the last follow-up after radiotherapy,26(74.3%)patients had no evidence of disease,7(20%)patients had DM,2(5.9%)patients died of DM,and 1 patient with DM was lost to follow-up.Univariate analyses showed that duration of symptoms,bone destruction,T stage classification,and wide excision surgery were risk factors influencing DM(P<0.05).The 5-year and 10-year OS rates after the initial surgery were 95.8%and 79.9%,respectively.The 5-year DM-free survival and disease-free survival rates after radiotherapy were 66.4%and 52.7%,respectively.CONCLUSION:^(125I)seed radiotherapy and local externalγ-ray radiotherapy may have similar therapeutic effects in preventing DM.Patients with T1/T2 stage disease have a better prognosis than those with T3/T4 stage disease. 展开更多
关键词 adenoid cystic carcinoma lacrimal gland ^^(125I)seed radiotherapy γ-ray radiotherapy surgical excision
下载PDF
DTI and pathological changes in a rabbit model of radiation injury to the spinal cord after ^(125)I radioactive seed implantation 被引量:4
7
作者 Xia Cao Le Fang +2 位作者 Chuan-yu Cui Shi Gao Tian-wei Wang 《Neural Regeneration Research》 SCIE CAS CSCD 2018年第3期528-535,共8页
Excessive radiation exposure may lead to edema of the spinal cord and deterioration of the nervous system. Magnetic resonance imaging can be used to judge and assess the extent of edema and to evaluate pathological ch... Excessive radiation exposure may lead to edema of the spinal cord and deterioration of the nervous system. Magnetic resonance imaging can be used to judge and assess the extent of edema and to evaluate pathological changes and thus may be used for the evaluation of spinal cord injuries caused by radiation therapy. Radioactive ^125I seeds to irradiate 90% of the spinal cord tissue at doses of 40–100 Gy (D90) were implanted in rabbits at T10 to induce radiation injury, and we evaluated their safety for use in the spinal cord. Diffusion tensor imaging showed that with increased D90, the apparent diffusion coefficient and fractional anisotropy values were increased. Moreover, pathological damage of neurons and microvessels in the gray matter and white matter was aggravated. At 2 months after implantation, obvious pathological injury was visible in the spinal cords of each group. Magnetic resonance diffusion tensor imaging revealed the radiation injury to the spinal cord, and we quantified the degree of spinal cord injury through apparent diffusion coefficient and fractional anisotropy. 展开更多
关键词 nerve regeneration BRACHYTHERAPY ^^125I radioactive seeds magnetic resonance imaging radiation injury of the spinal cord diffusion tensor imaging apparent diffusion coefficient fractional anisotropy neural regeneration
下载PDF
Dosimetry for ^(125) I radioactive seed implantation therapy for hepatocellular carcinoma 被引量:3
8
作者 Jin Lue Xiufeng Cao 《Journal of Nanjing Medical University》 2008年第5期269-272,共4页
Hepatocellular carcinoma (HCC) is an aggressive malignancy. Early lesions respond well to hepatic resection or liver transplantation. However, only a few of HCC patients are suitable for surgical intervention. Exter... Hepatocellular carcinoma (HCC) is an aggressive malignancy. Early lesions respond well to hepatic resection or liver transplantation. However, only a few of HCC patients are suitable for surgical intervention. External beam radiation and chemotherapy is poorly efficacious. In the last 20 years, HCCs belonging to the radiosensitive tumor group has been confirmed. Along with the development of new radiotherapy technology and facilities, the research about brachytherapy(especially ^125I seed implantation therapy) has provoked more interests in the world. Radioactive seed implantation therapy is a form of interstitial brachytherapy, with the property of local "conformal radiotherapy" and the advantages of minimal invasion, convenience, high performance, and minimal adverse effects. It is a promising therapy for HCC, however the dosimetry hasn' t yet been identified and lacks verification in prospective research. This report aims to further explore the best prescription dose and radioactivity for ^125I interstitial implantation brachytherapy for HCC. 展开更多
关键词 carcinoma hepatocellular/radiotherapy BRACHYTHERAPY radioactive seeds ^^125I
下载PDF
Relationship between miR-7-5p expression and ^(125)I seed implantation efficacy in pancreatic cancer and functional analysis of target genes 被引量:1
9
作者 Tingting Hao Chaoqi Wang +3 位作者 Yingjie Song Wanyan Wu Xuetao Li Tao Fan 《Oncology and Translational Medicine》 CAS 2021年第4期177-182,共6页
Objective The aim of this study was to investigate the relationship between miR-7-5p expression and intertissue-^(125)I irradiation sensitivity in pancreatic cancer tissues and to analyze the function of target genes.... Objective The aim of this study was to investigate the relationship between miR-7-5p expression and intertissue-^(125)I irradiation sensitivity in pancreatic cancer tissues and to analyze the function of target genes.Methods Thirty-seven patients with unresectable pancreatic ductal adenocarcinoma(PDAC)treated with radioactive ^(125)I seed implantation were enrolled.RT-PCR was used to detect the expression level of miR-7-5p in cancer tissues and analyze the relationship between miR-7-5p expression and ^(125)I radiation sensitivity.Bioinformatic software and online tools were used to predict the miR-7-5p target genes and analyze their functional annotation and pathway enrichment.Results Radioactive ^(125)I seed implantation was followed up for 2 months.The objective response rate of the miR-7-5p high expression group was 65.0%(13/20),whereas the objective response rate of the miR-7-5p low expression group was 5.88%(1/17),and the difference between the two groups was statistically significant(χ^(2)=13.654,P<0.001).A total of 187 target genes were predicted using three databases.GO functional annotation showed that target genes were mainly involved in cellular response to insulin stimulus,regulation of gene expression by genetic imprinting,cytosol,peptidyl-serine phosphorylation,bHLH transcription factor binding,cargo loading into vesicles,cellular response to epinephrine stimulus,and nucleoplasm.KEGG pathway enrichment analysis showed that target genes were mainly involved in the ErbB signaling pathway,HIF-1 signaling pathway,axon guidance,longevity regulatory pathway,endocrine resistance,glioma,choline metabolism in cancer,and EGFR tyrosine kinase inhibitor drug resistance.Molecular complex detection analysis by Cytoscape revealed that PIGH,RAF1,EGFR,NXT2,PIK3CD,PIK3R3,ERBB4,TRMT13,and C5orf22 were the key modules of miR-7-5p target gene clustering.Conclusion The expression of miR-7-5p in pancreatic cancer tissues positively correlated with the radiosensitivity of ^(125)I seeds.Via targeted gene regulation,miR-7-5p acts on the network of multiple signaling pathways in PDAC and participates in its occurrence and development.Thus,miR-7-5p may become a predictive index of ^(125)I seed implantation therapy sensitivity in PDAC patients. 展开更多
关键词 miR-7-5p pancreatic cancer ^^(125)I radioactive seed implantation
下载PDF
^(125)I粒子永久性植入组织间放射治疗肝癌 被引量:44
10
作者 罗开元 郑江华 +4 位作者 李波 邵庆华 杨国凯 赵泉 杨嵘 《肝胆胰外科杂志》 CAS 2004年第1期29-31,共3页
目的 :探讨12 5I组织间放射治疗肝癌的疗效。方法 :选择肝癌患者 84例 ,随机分为对照组 (A组 )与治疗组 (B组 ) ,A组 4 2例行手术治疗 (根治手术或姑息手术 )和化疗 ;B组 4 2例 ,除施行A组的治疗方案外 ,另行术中永久植入12 5I粒子。结... 目的 :探讨12 5I组织间放射治疗肝癌的疗效。方法 :选择肝癌患者 84例 ,随机分为对照组 (A组 )与治疗组 (B组 ) ,A组 4 2例行手术治疗 (根治手术或姑息手术 )和化疗 ;B组 4 2例 ,除施行A组的治疗方案外 ,另行术中永久植入12 5I粒子。结果 :术前、术后 1w及 3个月内血象虽有显著差异 ,但均在正常范围内 ,免疫指标前后变化无统计学意义。A组 :12个月、2 4个月、36个月局部复发率分别为 4 1.7%、5 0 .0 %和 5 9.5 % ;12个月、2 4个月、36个月局部生存率分别为 81.3%、6 3.4 %和 4 7.6 %。B组 :12个月、2 4个月、36个月局部复发率分别为 0、6 .7%和 11.9% ;生存率分别为 94 .7%、87.5 %和 78.4 % ,两组的局部复发率及生存率有显著性差异 (P <0 .0 5 )。结论 :12 5I组织间放射治疗肝癌方法简单、安全 ,近期疗效确切 ,是治疗癌症的理想方法之一。 展开更多
关键词 组织间放疗 ^^125 I粒子 植入 肝肿瘤
下载PDF
CT引导下放射性^(125)I粒子置入治疗脊柱转移性肿瘤的价值 被引量:26
11
作者 柳晨 王俊杰 +5 位作者 孟娜 刘晓光 姜亮 马永强 韩嵩博 袁慧书 《中国脊柱脊髓杂志》 CAS CSCD 北大核心 2011年第3期226-229,共4页
目的:探讨CT引导下放射性125I粒子置入治疗脊柱转移性肿瘤的价值。方法:14例无法手术切除或放化疗的脊柱转移性肿瘤患者,均在CT引导下行放射性125I粒子置入术。置入术前应用三维治疗计划系统制定粒子置入计划。术中根据CT影像采取不同... 目的:探讨CT引导下放射性125I粒子置入治疗脊柱转移性肿瘤的价值。方法:14例无法手术切除或放化疗的脊柱转移性肿瘤患者,均在CT引导下行放射性125I粒子置入术。置入术前应用三维治疗计划系统制定粒子置入计划。术中根据CT影像采取不同置入针排列方式种植粒子,粒子间距0.5~1.0cm。根据肿瘤大小及对放射线敏感程度置入粒子数范围26~145颗,粒子活度范围0.50~0.80mCi。术后即刻复查CT观察粒子分布情况,并再次应用三维治疗计划系统进行剂量验证。结果:14例患者均顺利完成手术。所有病例随访1~75个月,中位随访时间12.0个月。局部有效率50.0%,中位局部控制时间为26.0个月,1年、2年和3年局部控制率分别为62.5%、50.0%和37.5%。中位生存时间11.0个月,1年、2年和3年生存率分别为50.0%、41.7%和20.8%。神经功能保留率和恢复率分别为92.9%(13/14)和71.4%(10/14)。镇痛有效率和疼痛完全缓解率分别为78.6%(11/14)和64.3%(9/14)。结论:CT引导下放射性125I粒子置入治疗脊柱转移性肿瘤安全,并发症少,疗效确切,可作为不宜手术切除或放化疗患者的补充治疗方式。 展开更多
关键词 CT引导 125I粒子 脊柱肿瘤 转移 近距离治疗
下载PDF
放射性125^I粒子组织间植入治疗胰腺癌的疗效分析 被引量:23
12
作者 张长宝 田建明 +3 位作者 吕桃珍 左长京 邵成伟 生晶 《介入放射学杂志》 CSCD 北大核心 2009年第4期281-284,共4页
目的探讨125I粒子组织间植入治疗胰腺癌的疗效。方法回顾性分析2005年7月至2008年6月我院采用125I粒子植入治疗的33例胰腺癌患者资料。肿瘤最大径1.5~6.6cm,平均3.7cm。结果粒子植入术后,止痛有效率为60.6%,术后3个月内4例死亡。术后3... 目的探讨125I粒子组织间植入治疗胰腺癌的疗效。方法回顾性分析2005年7月至2008年6月我院采用125I粒子植入治疗的33例胰腺癌患者资料。肿瘤最大径1.5~6.6cm,平均3.7cm。结果粒子植入术后,止痛有效率为60.6%,术后3个月内4例死亡。术后3个月CT复查,部分缓解(PR)8例,疾病稳定(SD)13例,疾病进展(PD)8例,总有效率27.6%。全组生存时间2~19个月,中位生存时间5.1个月,6例仍在随访中。随访中无胰瘘和胃肠道出血等严重并发症,有51粒粒子(18例患者)丢失,11粒粒子(5例患者)出现迁移,移至肠道9粒,肝、脾各1粒,未见放射性肠炎和肝功能改变。结论125I粒子组织间植入治疗胰腺癌在疼痛缓解方面疗效明确,但本组病例Ⅳ期患者较多,未取得较好的疗效,具体疗效还有待于大样本前瞻性队列研究证实。 展开更多
关键词 胰腺癌 近距离放射疗法 125I粒子植入
下载PDF
放射性^(125)I粒子植入术后患者及密切接触者的剂量监测 被引量:11
13
作者 岳瑶 刘海生 +3 位作者 王俊杰 冉维强 黄毅 王文学 《现代肿瘤医学》 CAS 2010年第2期217-219,共3页
目的:分析125I粒子植入术后对患者、患者周边及密切接触者的受照剂量率并估算年剂量,及在该剂量率的条件下达到剂量限值所需要的时间。方法:采用热释光剂量计检测20例125I植入后的患者体表、病人家属、病人床边、邻床床边及医护人员的... 目的:分析125I粒子植入术后对患者、患者周边及密切接触者的受照剂量率并估算年剂量,及在该剂量率的条件下达到剂量限值所需要的时间。方法:采用热释光剂量计检测20例125I植入后的患者体表、病人家属、病人床边、邻床床边及医护人员的受照剂量率,并根据公式推算这些检测点受到照射的年剂量,及在该剂量率的条件下达到剂量限值时所需要的时间。结果:患者体表平均剂量率为214.54μGy/h,其中头颈部肿瘤、腹部肿瘤、前列腺癌及其他肿瘤患者体表的平均剂量率分别为4193.18μGy/h,22.97μGy/h,160.34μGy/h,9656.32μGy/h,年当量剂量平均值为441.25mSv,其中头颈部肿瘤、腹部肿瘤、前列腺癌及其他肿瘤患者体表的年当量剂量分别为8624.14mSv,47.24mSv,329.77mSv,19860.21mSv。累计剂量达到5mSv和1mSv所需要的平均时间分别为:23.44h和4.67h,其中头颈部肿瘤、腹部肿瘤、前列腺癌及其他肿瘤患者累计剂量达到5mSv和1mSv所需要的平均时间分别为:1.19h和0.24h、230.07h和44.00h、31.42h和6.25h、0.52h和0.10h。与患者密切接触者及位于其周边位点的年当量剂量均值最大为0.01 mSv。结论:125I粒子组织间近距离治疗术后病人,其周边环境及其密切接触者是安全的。 展开更多
关键词 125I粒子 热释光 剂量
下载PDF
^(125)I粒子治疗前列腺癌医护人员受照剂量分析 被引量:7
14
作者 岳瑶 刘海生 +3 位作者 郭呈祥 王俊杰 冉维强 黄毅 《中国现代医学杂志》 CAS 北大核心 2015年第30期62-64,共3页
目的分析125I粒子治疗前列腺癌医护人员的受照剂量和剂量率。方法采用热释光剂量计检测125I植入术前、植入术中、植入术后医护人员的受照剂量,并计算出剂量率。结果植入术前医护人员的指尖、眼睛、甲状腺、胸部的剂量率分别是30.26、1.8... 目的分析125I粒子治疗前列腺癌医护人员的受照剂量和剂量率。方法采用热释光剂量计检测125I植入术前、植入术中、植入术后医护人员的受照剂量,并计算出剂量率。结果植入术前医护人员的指尖、眼睛、甲状腺、胸部的剂量率分别是30.26、1.80、2.23、0.00μGy/h。植入术中放疗科医师、影像科医师、外科医师、外科医师助手、器械护士、麻醉科医师以及参观人员的剂量率分别是0.71、3.35、0.48、22.59、8.12、0.00及0.00μGy/h。植入术后医护人员的受照剂量为本底水平。结论 125I粒子组织间近距离治疗前列腺癌医护人员是安全的。 展开更多
关键词 125I粒子 热释光 剂量 医护人员
下载PDF
薄层CT对^(125)I粒子植入治疗非小细胞肺癌的质量控制和保证的意义 被引量:10
15
作者 王琳 李小东 +4 位作者 张遵城 郑广钧 郭永涛 张雪宁 戴越 《天津医药》 CAS 北大核心 2014年第4期341-344,共4页
目的探讨薄层CT扫描在125I粒子植入治疗非小细胞肺癌(NSCLC)各个环节中的临床价值。方法确诊的137例NSCLC患者,植入前CT扫描进行靶区勾画,应用治疗计划系统(TPS)制定植入方案;CT引导植入,并在植入过程中逐层扫描已植入粒子,进行实时位... 目的探讨薄层CT扫描在125I粒子植入治疗非小细胞肺癌(NSCLC)各个环节中的临床价值。方法确诊的137例NSCLC患者,植入前CT扫描进行靶区勾画,应用治疗计划系统(TPS)制定植入方案;CT引导植入,并在植入过程中逐层扫描已植入粒子,进行实时位置验证和修正;植入后CT扫描协助进行放射剂量学验证,必要时调整粒子的分布和数量,使剂量分布符合有效和微创的原则;定期随访和疗效评价也需要CT检查。结果剂量-体积直方图(DVH)均显示靶区放射剂量分布能满足处方剂量要求,周围危及器官的平均照射剂量明显低于正常组织耐受剂量;137例患者中129例(94%)植入粒子数与TPS计划的植入方案一致;植入治疗后6个月CT扫描显示局部控制总有效率为91.9%,1年和2年生存率分别为91.2%和50.4%;无治疗相关的严重并发症。结论薄层CT应用于125I粒子植入治疗NSCLC过程的各环节,尤其是在粒子植入的质量保证和质量控制方面具有重要的、不可替代的临床价值。 展开更多
关键词 非小细胞肺 碘放射性同位素 近距离放射疗法 体层摄影术 X线计算机 质量控制 125I粒子 质量保证
下载PDF
门脉支架及TACE联合或未联合血管内植入碘-125(^(125)I)粒子条治疗肝癌合并门脉主干癌栓(MPVTT)的随机对照研究 被引量:27
16
作者 吴林霖 罗剑钧 +5 位作者 颜志平 方主亭 张雯 张学彬 王建华 王小林 《复旦学报(医学版)》 CAS CSCD 北大核心 2013年第3期354-359,共6页
目的随机分组对照探讨经动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)及门脉内植入支架联合或未联合血管内植入碘-125(125Ⅰ)粒子条治疗原发性肝癌(hepatocellular carcinoma,HCC)伴门脉主干癌栓(main portal vein tum... 目的随机分组对照探讨经动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)及门脉内植入支架联合或未联合血管内植入碘-125(125Ⅰ)粒子条治疗原发性肝癌(hepatocellular carcinoma,HCC)伴门脉主干癌栓(main portal vein tumor thrombus,MPVTT)的临床疗效。方法选择2009年2月至2011年4月于我院接受肝癌TACE治疗的60例HCC合并MPVTT患者(男52例,女8例,平均年龄53岁)进行随机分组。A组在门脉内植入支架及125Ⅰ粒子条,B组仅在门脉内植入支架,每组30例。分别对两组患者进行生存期、支架通畅率及相关不良事件的分析。结果门脉内植入支架及125Ⅰ粒子条介入技术成功率为100%,无严重手术并发症及相关不良事件发生。A组和B组患者的中位生存期分别为335天及142天(P=0.002,HR=2.683)。A组和B组患者支架的中位通畅期分别为340天及190天(P=0.038,HR=2.252)。结论门脉支架及TACE联合血管内植入125I粒子条能明显延长HCC伴MPVTT患者的支架通畅期、生存期,提高患者生存质量,是临床治疗HCC合并MPVTT的重大突破。 展开更多
关键词 原发性肝癌(HCC) 门脉主干癌栓(MPVTT) 经动脉化疗栓塞(TACE) 碘-125粒子条 门脉支架
下载PDF
CT引导下^(125)I粒子植入联合GP方案治疗局部进展期胰腺癌 被引量:14
17
作者 杨文魁 陈勇 +1 位作者 王磊 吴晓东 《世界华人消化杂志》 CAS 北大核心 2014年第10期1455-1459,共5页
目的:探讨computed tomography(CT)引导下125I粒子植入联合吉西他滨及顺铂(gemcitabineand cisplatin,GP)方案化疗治疗局部进展期胰腺癌的疗效.方法:88例不能手术切除局部进展期胰腺癌(locally advanced pancreatic carcinoma,LAPC)患... 目的:探讨computed tomography(CT)引导下125I粒子植入联合吉西他滨及顺铂(gemcitabineand cisplatin,GP)方案化疗治疗局部进展期胰腺癌的疗效.方法:88例不能手术切除局部进展期胰腺癌(locally advanced pancreatic carcinoma,LAPC)患者随机分为2组:A组(粒子植入+化疗组)45例,在局麻下行CT引导125I粒子植入术,术后10-14 d内依据患者体质情况开始行GP方案化疗,具体方案同化疗组;B组(化疗组)43例,应用"GP方案"全身化疗,具体:吉西他滨1000mg/m2(d1,8)+顺铂75 mg/m2分割呈1-4 d应用,21 d为1疗程.2组患者均按期完成4个周期化疗后进行疗效评价.患者治疗后l、2、3 mo行增强CT扫描及CA199复查,以后为每3 mo 1次,共随访30 mo.结果:A组临床受益率与B组临床受益率比较P<0.05,有统计学意义;A组平均生存时间与B组平均生存时间比较P<0.05,有统计学意义.2组88例患者中均按计划顺利完成,无1例术后及化疗后出现胰漏、出血、脏器穿孔及Ⅳ度骨髓抑制等严重不良反应.结论:CT引导下125I粒子植入联合GP方案综合治疗局部进展期胰腺癌是一种安全、有效的治疗手段. 展开更多
关键词 局部进展期胰腺癌 I125粒子植入 化疗
下载PDF
^(125)碘粒子植入联合化疗治疗中晚期肺癌 被引量:8
18
作者 陈志军 周爱清 +2 位作者 刘震天 王文俊 吴真 《南昌大学学报(医学版)》 CAS 2011年第8期60-62,65,共4页
目的探讨125碘(125I)粒子植入联合化疗治疗中晚期肺癌的临床价值。方法选择不同病理类型中晚期非小细胞肺癌181例:CT引导下经皮穿刺植入125I粒子,3d后给予顺铂+吉西他滨化疗(Ⅰ组,26例);单纯给予顺铂+吉西他滨化疗(Ⅱ组,66例);在给予50... 目的探讨125碘(125I)粒子植入联合化疗治疗中晚期肺癌的临床价值。方法选择不同病理类型中晚期非小细胞肺癌181例:CT引导下经皮穿刺植入125I粒子,3d后给予顺铂+吉西他滨化疗(Ⅰ组,26例);单纯给予顺铂+吉西他滨化疗(Ⅱ组,66例);在给予50~70Gy外照射同时给予顺铂+吉西他滨化疗(Ⅲ组,89例)。治疗6个月后评价3组疗效及毒副作用。结果Ⅰ组有效率76.9%(20/26),其中完全缓解率(CR)7.7%(2/26),部分缓解率(PR)69.2%(18/26),无效率(NC)15.4%(4/26),进展率(PD)7.7%(2/26);Ⅱ组有效率53.0%(35/66),其中CR、PR、NC、PD分别为3.0%(2/66)、50.0%(33/66)、31.8%(21/66)和15.2%(10/66);Ⅲ组有效率84.3%(75/89),其中CR、PR、NC、PD分别为7.9%(7/89)、71.9%(64/89)、16.9%(15/89)和3.3%(3/89)。Ⅱ组与Ⅰ、Ⅲ组有效率比较,差异有统计学意义(P<0.05),Ⅲ组与Ⅰ组有效率比较,差异无统计学意义(P>0.05)。粒细胞减少发生率Ⅰ、Ⅱ、Ⅲ组分别为38.5%(10/26)、34.8%(23/66)、60.7%(54/89),Ⅰ组与Ⅱ组比较差异无统计学意义(P>0.05),Ⅲ组与Ⅰ、Ⅱ组比较差异有统计学(P<0.05)。结论 125I粒子植入联合化疗治疗晚期肺癌有效率高,且毒副作用低。 展开更多
关键词 125I粒子 化疗 放疗 中晚期肺癌
下载PDF
腹腔镜肝切除联合射频消融及^(125)I粒子植入治疗肝癌 被引量:6
19
作者 向国安 陈开运 +5 位作者 王汉宁 高鹏 张刚庆 郑权 陈诗华 陈规划 《中国微创外科杂志》 CSCD 2007年第2期123-124,共2页
目的探讨应用腹腔镜下肝切除联合射频消融及125I粒子植入治疗肝癌的疗效。方法26例肝癌患者,左肝叶肿瘤12例,右肝叶肿瘤11例,左右肝叶均有肿瘤3例。总病灶为34个,肿瘤直径2.8~13.0cm。所有患者均接受腹腔镜肿瘤切除、125I粒子植入和射... 目的探讨应用腹腔镜下肝切除联合射频消融及125I粒子植入治疗肝癌的疗效。方法26例肝癌患者,左肝叶肿瘤12例,右肝叶肿瘤11例,左右肝叶均有肿瘤3例。总病灶为34个,肿瘤直径2.8~13.0cm。所有患者均接受腹腔镜肿瘤切除、125I粒子植入和射频消融。结果所有患者均顺利行125I粒子植入、射频消融或腹腔镜肿瘤切除,无中转开腹,术中超声发现新病灶2个。8个病灶位于右后内叶仅行超声刀汽化及射频消融、125I粒子植入,28个边缘病灶行射频消融、腹腔镜肿瘤切除和125I粒子植入。随访12~25个月(平均22.3月),1年生存率为92.3%(24/26),治疗的36个病灶中有3个在切除部位复发。所有患者无严重并发症。结论联合应用125I粒子植入和射频消融、腹腔镜切除肝癌安全,微创,疗效确切,存活率高,复发少,术后恢复快。 展开更多
关键词 腹腔镜 肝癌 射频消融 ^^125Ⅰ粒子
下载PDF
I^(125)粒子植入在胰腺恶性肿瘤治疗中的疗效分析 被引量:7
20
作者 吴汉青 吴河水 +2 位作者 杨智勇 王春友 原伟伟 《世界华人消化杂志》 CAS 北大核心 2009年第28期2951-2954,共4页
目的:分析姑息性手术联合I125粒子植入和化疗对晚期胰腺癌患者的疗效.方法:回顾性分析我科2004-2008年收治的晚期胰腺癌患者149例,按治疗方法分为2组,姑息手术+I125粒子植入+化疗62例(A组),姑息手术+化疗87例(B组).比较2组患者客观有效... 目的:分析姑息性手术联合I125粒子植入和化疗对晚期胰腺癌患者的疗效.方法:回顾性分析我科2004-2008年收治的晚期胰腺癌患者149例,按治疗方法分为2组,姑息手术+I125粒子植入+化疗62例(A组),姑息手术+化疗87例(B组).比较2组患者客观有效率(OTR)、临床受益率(CBR)、中位生存期以及并发症发生率.结果:与B组相比,A组患者临床受益率,中位生存期差异有统计学差异(χ2=7.361,10.090,P<0.05),而客观有效率与并发症发生率差异无统计学差异(P>0.05).结论:姑息性手术联合I125粒子植入和术后化疗治疗晚期胰腺癌患者,是一种安全有效的治疗方法. 展开更多
关键词 胰腺肿瘤 姑息手术 ^I^125粒子植入 术后化疗
下载PDF
上一页 1 2 9 下一页 到第
使用帮助 返回顶部